CAV1 and breast cancer: Similarly, in a xenograft mouse model where MDA-MB-231 breast cancer cells were co-injected with wild-type or Cav-1-deficient fibroblasts, the Cav-1-deficient fibroblasts led to enhanced glycolytic enzyme synthesis to provide energy-rich metabolites (e.g., lactate), thus increasing cancer growth and angiogenesis [156].